Results 51 to 60 of about 3,115 (154)

Association of LDL‐C With Angiographic Thrombus Burden in Patients With ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background High thrombus burden (HTB) during primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial infarction (STEMI) is associated with adverse outcomes. Low‐density lipoprotein cholesterol (LDL‐C) is a key driver of atherosclerosis, but its direct role in acute thrombus formation remains unclear.
Tuo Han, Hytham H. Al-Samawi, Jing Xiao, Xiyu Gao, Gen Liu, Di Bai, Chunyan Zhang, Wei Jiang, Yan Zhang, Irfan Ahmad   +9 more
wiley   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1463-1476, December 2025.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source

Comparison between Bolus Intracoronary versus Bolus Intravenous Injection Regimens of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Anterior ST-Segment Elevation Myocardial Infarction

Рациональная фармакотерапия в кардиологии, 2019
Background. Eptifibatide achieves high local concentration via direct intracoronary (I/V) injection as it promotes clot disaggregation, but it remains unclear if it is of superior benefit than the routine intravenous (I/V) administration. Aim.
Mohamed Hassan Nab, Shaimaa Mostafa, Khaled Elrabat, Hamza Kabil, Neama Elmelegy   +4 more
doaj   +1 more source

Safety and efficacy of enoxaparin versus unfractionated heparins in conservatively managed patients with acute coronary syndrome: a systematic review

Journal of Pharmacy Practice and Research, Volume 55, Issue 6, Page 447-457, December 2025.
Abstract Aim Guidelines recommend initial anticoagulant management of acute coronary syndrome (ACS) with low molecular weight heparin (LMWH) such as enoxaparin or unfractionated heparin (UFH). Systematic reviews evaluate early trials in the context of multiple other medications or during percutaneous coronary intervention (PCI) only.
Krishna Doshi, Mark Jones, Laetitia Hattingh   +2 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions

The Egyptian Heart Journal, 2014
Background: Platelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation. Aim: To compare the degree of platelet aggregation inhibition
Yasser Sadek Nassar, Mohamed Laimud, Mohamed Afify, Mohamed Ashraf Shawky   +3 more
doaj   +1 more source

Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention

Рациональная фармакотерапия в кардиологии, 2020
Recently, there has been a positive trend to reduce mortality from myocardial infarction. One of the reasons for such dynamics is the development of angiographic service in our country and the increase in the number of primary percutaneous coronary ...
A. S. Tereshchenko, Е. V. Merkulov, A. M. Samko   +2 more
doaj   +1 more source

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper

Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini, Alla Nakonechna, Annick Barbaud, Sevim Bavbek, Gianfranco Calogiuri, Inmaculada Doña, Violeta Kvedariene, Jose Julio Laguna Martinez, Serena Liberati, Mauro Pagani, Antonino Romano   +10 more
wiley   +1 more source

Biomimetic Cell Membrane‐Coated Scaffolds for Enhanced Tissue Regeneration

Advanced Materials, Volume 37, Issue 40, October 9, 2025.
This review examines the development and use of cell membrane‐coated scaffolds in tissue engineering. Bioinspired phospholipid and glycocalyx coatings enhance anti‐fouling, anti‐thrombogenic, and selective molecular recognition properties. Native cell membrane coatings further support cell‐specific interactions, immune modulation, and reduced bacterial
Carmen Alvarez‐Lorenzo, Alejandro Ramirez‐Romero, Diana Peixoto, Maria Vivero‐Lopez, Isabel Rodríguez‐Moldes, Angel Concheiro   +5 more
wiley   +1 more source